Clinical neuropharmacology
-
Clin Neuropharmacol · Jan 2014
Randomized Controlled Trial Multicenter StudyLong-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized study.
This study investigated the long-term safety of rivastigmine (12 mg/d capsules, 9.5 mg/24 h patch) and effects on motor symptoms in patients with mild-to-moderately severe Parkinson disease dementia. ⋯ This study supports the long-term safety of rivastigmine in Parkinson disease dementia. The rate of worsening of motor symptoms was in the range expected due to the natural progression of Parkinson disease, no new or unexpected safety issues emerged in the long-term.